Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell ...

A live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of the Company's website at ...

Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a Letter of Support (LoS ...

Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

Bridge to Life Ltd., a leading provider of organ preservation solutions and organ perfusion equipment, has announced that more than 5,0001 liver perfusions worldwide have been successfully performed u ...

Corporate media began raising their warnings and concerns about Robert F. Kennedy Jr. on Thursday, almost immediately after ...

Once dominated by PVC, the market has largely shifted to polyolefin as a more adaptable, eco-friendlier alternative, offering ...

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 ...